All Reports Events Blogs Videos
Showing 46 results
  • See Us At
    July 21, 2026

    Join Sanket Anshuman, Practice Director at Everest Group, to explore how pharmacovigilance (PV) is evolving from a compliance-driven function to an AI-enabled, intelligence-led safety model. Discover how organizations can leverage AI, automation, and real-world data to…
  • PEAK Matrix®
    July 09, 2026

    Enterprises are rethinking recruitment strategies as hiring demand stabilizes following a prolonged market slowdown, while continuing to navigate economic uncertainty, budget pressures, and persistent skill shortages. Organizations are increasingly seeking flexible recruitment models that can scale…
  • Viewpoint
    July 07, 2026

    AI is no longer simply changing how talent decisions are made; it is reshaping how organizations define talent, structure work, and build workforce advantage. As enterprises accelerate AI adoption, the focus is expanding beyond process transformation…
  • Viewpoint
    June 29, 2026

    The post-approval phase represents one of the most complex and strategically critical stages in the life sciences product life cycle, requiring enterprises to ensure continuous safety monitoring, regulatory compliance, and real-world performance optimization. With increasing diverse…
  • Viewpoint
    June 23, 2026

    Artificial intelligence (AI) is rapidly becoming a core component of Talent Acquisition (TA) and HR strategy as organizations navigate evolving skill requirements, rising application volumes, and increasing pressure to deliver measurable business outcomes. While AI adoption…
  • Thematic Report
    May 04, 2026

    The global Clinical Research Organization (CRO) market is undergoing a transformation, shaped by rising clinical trial complexity, increasing regulatory requirements, and growing demand for faster, more efficient drug development. CROs continue to play a pivotal role…
  • Viewpoint
    April 28, 2026

    The global safety database market is at an inflection point, driven by increasing complexities in Pharmacovigilance (PV) operations, growing regulatory expectations, and rapid expansion of data sources such as real-world evidence, digital health tools, and patient-generated…
  • LinkedIn Live
    Nov. 19, 2025

    In an evolving landscape where analyst relations (AR) shape market perception and business success, leaders continued to look for proven tactics embraced by experienced AR professionals. Everest Group’s Katrina Menzigian, along with industry experts from other…
  • Market Insights™
    Nov. 05, 2025

  • Blog
    Nov. 02, 2025

    The clinical outsourcing market is undergoing a transition with the emergence of specialist-focused Clinical Research Organizations (CROs). A specialist CRO concentrates its expertise in a defined area, such as a therapeutic focus, trial phase or technology, or geographic niche, rather than offering broad,…
  • State of the Market
    Oct. 01, 2025

    The surge in case volumes, more stringent regulatory demands, and therapeutic areas’ rising complexities are significantly transforming pharmacovigilance (PV). As the industry adapts to more tailored reporting requirements and longer patient monitoring periods, enterprises are under…
  • Provider Compendium
    Sep. 30, 2025

    In recent years, life sciences enterprises have reoriented their R&D investments, prioritizing pipeline efficiency and a strategic focus on large and novel molecules. This shift has intensified efforts around cost containment and created a stronger need…
  • Provider Compendium
    Sep. 16, 2025

    Pharmacovigilance (PV) operations have become a strategic priority for life sciences enterprises facing heightened regulatory scrutiny, evolving safety standards, and growing complexity across global markets. This report provides an in-depth assessment of 12 leading PV service…
  • Webinar Deck
    July 31, 2025

    Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping…
  • Event
    July 29, 2025

    Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping…
  • PEAK Matrix®
    July 16, 2025

    In recent years, life sciences enterprises have reprioritized and overhauled their R&D investments. They now focus on streamlining their pipelines and shifting toward new and large molecules. This transformation has compelled aggressive cost containment initiatives, prompting…
  • Viewpoint
    June 12, 2025

    Life sciences enterprises are increasingly turning to Real-world Evidence (RWE) as an essential input for decision-making across the product life cycle – from early-stage R&D to post-market access and safety. RWE offers validated insights into treatment…
  • Blog
    May 23, 2025

    On May 12, 2025, President Donald Trump signed a high-impact executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” The order directed the U.S. Department of Health and Human Services (HHS) to implement a…
  • PEAK Matrix®
    April 03, 2025

    Pharmacovigilance (PV) has evolved into a strategic imperative, driven by intensified regulatory scrutiny and an increasing focus on patient safety. Pharmaceutical companies now face a rapidly evolving landscape characterized by rising adverse event volumes, fragmented real-world…
  • Viewpoint
    May 02, 2024

    The healthcare industry is transforming rapidly, driven by rising costs, stricter regulations, and a growing emphasis on member experience. This pressure highlights the need for healthcare payers to improve efficiency and effectiveness, especially in light of…

Items per page